Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post by Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program, on X:

“With this practice-changing study we learned that ‘some pembro’ is better than ‘no pembro’ in patients scheduled for preop chemo.

Yet, by my no means does it confirm that ‘more pembro’ after surgery further helps already-responders (MPR and pCR) or non-responders.”

Quoting Jonathan Spicer’s post:

“KN671 OS and HRQoL!

Check it out.”

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Prof Se-Hoon Lee, Prof Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gastón L Martinengo, Prof Olivier Bylicki, Delvys Rodríguez-Abreu, Jamie E Chaft, Prof Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M Keller, Ayman Samkari, Shugeng Gao

Drew Moghanaki

Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo